This is a working overview of PPARδ agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-03 and is reviewed periodically as new material appears.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
=== Read trimming === Sometimes, the raw reads produced by the sequencer are correct and precise only in a fraction of their length. Using the entire read may introduce artifacts in the downstream analyses like genome assembly, SNP calling, or gene expression estimation. Two classes of trimming programs have been introduced, based on the window-based or the running-sum classes of algorithms. This is a partial list of the trimming algorithms currently available, specifying the algorithm class they belong to:
It reaches from here all the way back to where it came from." Apparently because of his status as The One, he has a direct connection to the Source in the real world, and can therefore affect everything connected to it, including Sentinels, although the first use of this ability overwhelms him and he falls into a coma as his mind somehow plugs into the Matrix without a physical connection. Neo also begins to perceive everything connected to the Source, including the Machine City itself, as silhouettes of golden light. This ability becomes beneficial after he is blinded in the fight against Smith/Bane, thus he is able to see Smith/Bane and kill him. In The Matrix Resurrections, the resurrected Neo at first doesn't have access to his powers, although he slowly regains them over time, particularly during his fight with Smith. Neo is now able to create powerful telekinetic shockwaves, particularly when touching Trinity, and while he can still stop bullets, it appears to take him more effort. At one point, he telekinetically deflects a missile into a helicopter and shields himself from Smith smashing a porcelain sink down on his head. However, he is unable to fly while trying to escape from the Analyst's forces after reuniting with Trinity or after jumping off of a roof. Instead, Trinity develops the ability to fly and takes them both to safety. Neo appears to have regained his full powers by the end of the movie as he and Trinity fly off together after confronting the Analyst.
Because of the botched living donor kidney transplant at UPMC, the federal Organ Procurement Transplant Network (OPTN) put UPMC's transplant program on probation, a rarely used form of discipline handed down for some of the most serious transplant errors. The OPTN said it meted out the discipline not only because of the kidney transplant error, but because UPMC's transplant program was found to have problems in its communication and documentation procedures before. In April 2009, rival West Penn Allegheny Health System filed an antitrust lawsuit against the UPMC and health insurer Highmark, claiming a conspiracy to create a monopoly. The lawsuit was later dismissed with prejudice. West Penn Allegheny filed an appeal of this judgment. Upon appeal, the case was unanimously reinstated by the US Third Circuit Court of Appeals. In October 2009, UPMC's administration decision to close UPMC Braddock hospital resulted in multiple protest and lawsuits by community groups who disputed UPMC's claims that the hospital was losing money and was underutilized. The facility, now demolished in preparation for redevelopment, closed in January 2010. In April 2013, UPMC has been criticized for paying low wages, and using unfair labor practices to thwart efforts by employees to unionize, as alleged in the Service Employees International Union's complaint to the National Labor Relations Board. In addition, critics have accused the system of using noncompete agreements, preventing workers from mobilizing, and suppressing wages.
== Industrial applications == Although the use of protecting groups is not preferred in industrial syntheses, they are still used in industrial contexts, e.g. sucralose (sweetener) or the Roche synthesis of oseltamivir (Tamiflu, an antiviral drug) An important example of industrial applications of protecting group theory is the synthesis of ascorbic acid (Vitamin C) à la Reichstein.
Ataxia Severe hypoventilation Acute narrow-angle glaucoma Severe hepatic deficiencies (hepatitis and liver cirrhosis decrease elimination by a factor of two) Severe renal deficiencies (for example, patients on dialysis) Liver disorders Severe sleep apnea Severe depression, particularly when accompanied by suicidal tendencies Psychosis Pregnancy or breastfeeding Caution required in elderly or debilitated patients Coma or shock Abrupt discontinuation of therapy Acute intoxication with alcohol, narcotics, or other psychoactive substances (with the exception of hallucinogens or some stimulants, where it is occasionally used as a treatment for overdose) History of alcohol or drug dependence Myasthenia gravis, an autoimmune disorder causing marked fatiguability Hypersensitivity or allergy to any drug in the benzodiazepine class
Sources: en.wikipedia.org
The Allan Hills meteorite, the first to be identified on Earth as having come from the Moon, was discovered in the Transantarctic Mountains in Antarctica by John Schutt and Ian Whillans during the international ANSMET (Antarctic Search for Meteorites) expedition. The meteorite's mass was 31.4 grams (1.11 oz), slightly more than one ounce. Although the lunar meteorite Yamato 791197 had been found on November 20, 1979, it would not be identified as such until 1984. In 1996, examination of the The collapse of a swinging bridge over the Guaíra Falls waterfall killed 32 tourists in Brazil, on the border of Brazil and Paraguay near Guaira, while they were seeking a close view of the waterfall. Those killed fell from a height of 120 feet (37 m) and drowned in the Paraná River. Survivors said that some people on the bridge had been swinging it when the supportive cables snapped.
Cirrhosis is most commonly caused by medical conditions including alcohol-related liver disease, metabolic dysfunction–associated steatohepatitis (MASH – the progressive form of metabolic dysfunction–associated steatotic liver disease, previously called non-alcoholic fatty liver disease or NAFLD), heroin abuse, chronic hepatitis B, and chronic hepatitis C. Chronic heavy drinking can cause alcoholic liver disease. Liver damage has also been attributed to heroin usage over an extended period of time as well. MASH has several causes, including obesity, high blood pressure, abnormal levels of cholesterol, type 2 diabetes, and metabolic syndrome. Less common causes of cirrhosis include autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis that disrupts bile duct function, genetic disorders such as Wilson's disease and hereditary hemochromatosis, and chronic heart failure with liver congestion. Diagnosis is based on blood tests, medical imaging, and liver biopsy. Hepatitis B vaccine can prevent hepatitis B and the development of cirrhosis from it, but no vaccination against hepatitis C is available. No specific treatment for cirrhosis is known, but many of the underlying causes may be treated by medications that may slow or prevent worsening of the condition. Hepatitis B and C may be treatable with antiviral medications. Avoiding alcohol is recommended in all cases. Autoimmune hepatitis may be treated with steroid medications. Ursodiol may be useful if the disease is due to blockage of the bile duct.
=== Oral and sublingual === The first study of oral progesterone in humans was published in 1949. It found that oral progesterone produced significant progestational effects in the endometrium in women. Prior to this study, animal research had suggested that oral progesterone was inactive, and for this reason, oral progesterone had never been evaluated in humans. A variety of other early studies of oral progesterone in humans were also published in the 1950s and 1960s. These studies generally reported oral progesterone to be only very weakly active. Oral non-micronized progesterone was introduced as a pharmaceutical medication around 1953, for instance as Cyclogesterin (1 mg estrogenic substances and 30 mg progesterone tablets) for menstrual disturbances by Upjohn, though it saw limited use. Another preparation, which contained progesterone alone, was Synderone (trademark registered by Chemical Specialties in 1952). Sublingual progesterone in women was first studied in 1944 by Robert Greenblatt. Buccal progesterone tablets were marketed by Schering under the brand name Proluton Buccal Tablets by 1949. Sublingual progesterone tablets were marketed under the brand names Progesterone Lingusorbs and Progesterone Membrettes by 1951. A sublingual tablet formulation of progesterone has been approved under the brand name Luteina in Poland and Ukraine and remains marketed today. Progesterone was the first progestogen that was found to inhibit ovulation, both in animals and in women. Injections of progesterone were first shown to inhibit ovulation in animals between 1937 and 1939.
In December 2022, the British government announced that it planned to open the Independent Inquiry relating to Afghanistan to investigate extrajudicial killings that took place between 2010 and 2013, during the War in Afghanistan. This followed a detailed BBC Panorama investigation that found members of the SAS "repeatedly killed detainees and unarmed men in suspicious circumstances". Panorama spoke to witnesses who alleged that operatives justified the killings of unarmed persons by leaving weapons at the scenes of the shootings and that SAS squadrons competed '"with each other to get the most kills". According to the investigation, officers of the UK Special Forces were concerned over the number of reports of detainees being killed after reaching for hidden weapons. Allegedly, several raids ended with the deaths of more people than weapons recovered. The BBC visited the sites of some raids and heard from ballistics experts who interpreted the bullet patterns present as more indicative "of execution-style killings rather than firefights". A formal internal review was opened at the time, but evidence was never passed to military police. The inquiry was launched in March 2023, to be chaired by Lord Justice Haddon-Cave. In September 2024, an internal Ministry of Defence document written in 2019 was presented to the inquiry that concluded that the BBC Panorama allegations were "broadly accurate".
== Role in protection against oxidative stress == Aerobic bacteria inevitably are prone to the formation of reactive oxygen species due to the nature of their respiration processes. Under normal conditions these ROS strive to maintain a dynamic balance; however, this balance can often be disrupted by biotic or abiotic stressors such as superoxide radicals, endogenous lipids, DNA hydroperoxides, hydrogen peroxide, hydroxyl radicals, and hydroxy alkenals. Therefore, these susceptible organisms have intrinsic mechanisms to protect from oxidative damage; glutathione plays a key role in most of these antioxidant mechanisms. Once reduced, glutathione interacts with these reactive oxygen and nitrogen species. This interaction is catalyzed by GSTs and their involvement is vital for successful oxidation of glutathione. GSTs bind the ROS substrate at its hydrophobic alpha-helical C-terminal domain, as well as reduced glutathione to its glutathione-binding site on the N-terminal domain. These two domains are adjacent to each other on the enzyme, and together form the active site of the GST where the redox reaction occurs. Once both substrates are bound at the enzyme's active site, the monomeric GST interacts with another substrate-bound GST monomer and catalyzes a disulphide bridge between the two glutathione molecules. This yields the active dimeric enzyme structure. The reactive oxygen species then donates one electron to a glutathione molecule, completing the oxidation-reduction reaction and rendering it unable to perform oxidative damage to the cell.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.